NUVATION BIO INC (NUVB) Stock Price, Forecast & Analysis
USA • New York Stock Exchange • NYSE:NUVB • US67080N1019
NUVB Key Statistics, Chart & Performance
The current stock price of NUVB is 5.62 USD. In the past month the price decreased by -36.43%. In the past year, price increased by 136.13%.
NUVB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NUVB. When comparing the yearly performance of all stocks, NUVB is one of the better performing stocks in the market, outperforming 96.34% of all stocks.
NUVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NUVB. NUVB may be in some trouble as it scores bad on both profitability and health.
NUVB Financial Highlights
Over the last trailing twelve months NUVB reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by -48.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.15% | ||
| ROE | -66.74% | ||
| Debt/Equity | 0.61 |
NUVB Forecast & Estimates
16 analysts have analysed NUVB and the average price target is 11.42 USD. This implies a price increase of 103.27% is expected in the next year compared to the current price of 5.62.
For the next year, analysts expect an EPS growth of -16.6% and a revenue growth 2392.77% for NUVB
NUVB Ownership
NUVB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.41 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.57 | 564.909B | ||
| MRK | MERCK & CO. INC. | 22.13 | 293.697B | ||
| PFE | PFIZER INC | 8.82 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.8 | 117.3B | ||
| ZTS | ZOETIS INC | 18.5 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.5 | 25.214B | ||
| VTRS | VIATRIS INC | 5.68 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.06 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.39 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NUVB
Company Profile
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in New York City, New York and currently employs 291 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The firm's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Company Info
NUVATION BIO INC
1500 Broadway, Suite 1401
New York City NEW YORK 94103 US
CEO: David Hung
Employees: 291
Phone: 13322086102
NUVATION BIO INC / NUVB FAQ
What does NUVATION BIO INC do?
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in New York City, New York and currently employs 291 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The firm's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Can you provide the latest stock price for NUVATION BIO INC?
The current stock price of NUVB is 5.62 USD. The price decreased by -4.1% in the last trading session.
Does NUVATION BIO INC pay dividends?
NUVB does not pay a dividend.
How is the ChartMill rating for NUVATION BIO INC?
NUVB has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does NUVATION BIO INC belong to?
NUVATION BIO INC (NUVB) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the growth outlook for NUVATION BIO INC?
The Revenue of NUVATION BIO INC (NUVB) is expected to grow by 2392.77% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for NUVB stock?
NUVATION BIO INC (NUVB) currently has 291 employees.